Does the Presence of Accessory Renal Arteries Affect the Efficacy of Renal Denervation?  by Id, Dani et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 6 , N O . 1 0 , 2 0 1 3
ª 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 3 . 0 6 . 0 0 7Does the Presence of Accessory
Renal Arteries Affect the Efﬁcacy
of Renal Denervation?Dani Id, MD,* Benjamin Kaltenbach,* Stefan C. Bertog, MD,*y Marius Hornung, MD,*
Ilona Hofmann, MD,* Laura Vaskelyte, MD,* Horst Sievert, MD*
Frankfurt am Main, Germany; and Minneapolis, MinnesotaObjectives This study sought to assess the efﬁcacy of catheter-based renal sympathetic denervation
in patients with accessory renal arteries and to compare the blood pressure (BP)-lowering effect with
that observed in patients with bilateral single renal arteries after renal denervation.
Background Catheter-based renal sympathetic denervation causes signiﬁcant BP reductions in
patients with resistant hypertension.
Methods Seventy-four patients were included in this study. Patients were assigned to 2 main groups:
a bilateral single renal arteries group I (n ¼ 54) and an accessory renal arteries group II (n ¼ 20). Group
II consisted of 9 patients whose accessory renal arteries were all denervated (group IIa), and 11 patients
whose accessory renal arteries were not, or only incompletely, denervated (group IIb). The primary
endpoint was the change in ofﬁce systolic BP after 6 months.
Results The procedure was successful in all patients. Group I: mean BP at baseline was 166.2/89.4
 20.5/14.6 mm Hg and decreased by 16.6 (p < 0.001)/6.7 (p ¼ 0.016)  16.4/11 mm Hg at
6-month follow-up. Group II: mean BP at baseline was 164.2/89.1  19.9/15.4 mm Hg and decreased
by 6.2 (p ¼ 0.19)/0.2 (p ¼ 0.5)  19.7/11.3 mm Hg at 6-month follow-up. Patients in group IIa
had an ofﬁce BP reduction of 8.8 (p ¼ 0.2)/1.1  17.9/10.8 mm Hg and patients in group IIb
of 4.1 (p ¼ 0.55)/1.3  20.8/11.6 mm Hg. Similarly, signiﬁcant improvements in 24-h mean systolic
BP were seen in group I (8.3  17.4 mm Hg, p < 0.01), whereas none were seen in group II
(3.7  8.3 mm Hg, p ¼ 0.38).
Conclusions BP reduction achieved after renal denervation in patients with accessory renal arteries
is less pronounced than in patients with bilateral single renal arteries. (J Am Coll Cardiol Intv
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1086Arterial hypertension is a major risk factor for cardiovascular,
cerebrovascular, and renal morbidity and mortality (1).
Approximately 30% to 40% of the adult population has
arterial hypertension, and the prevalence is expected to in-
crease (2). Despite maximal medical management, depend-
ing on the population studied, the blood pressure (BP)
remains suboptimally controlled in approximately 10% of
individuals (3,4). Under these circumstances, catheter-based
renal sympathetic denervation has been shown to cause
a signiﬁcant BP reduction (5,6). Renal sympathetic nerves are
located primarily in the adventitia of the arteries supplying
the kidneys. The design of the most commonly used catheter
allows denervation in arteries 4 mm or larger in diameter.
However, accessory renal arteries, including dual renalSee page 1092arteries and early separation of pole arteries (Fig. 1), are
found in approximately 20% to 27% of patients (7–9). These
arteries are frequently smaller than 4 mm and therefore
not amenable to ablation with the currently approved
device. Nonetheless, they supply the kidney with sympatheticFigure 1. Anatomic Variations of
(A) Demonstrates dual renal artery
a separate right upper pole renal
Abbreviations
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BP = blood pressure
eGFR = estimated glomerular
ﬁltration ratenerve ﬁbers. Therefore, due to
concerns of incomplete denerva-
tion, patients with accessory
renal arteries have traditionally
been excluded from trial partici-
pation (5,10) or have not been
analyzed as a separate subgroup(6). Moreover, a case report suggests a less pronounced
BP reduction after incomplete denervation (11). A less
pronounced or absent BP reduction is conceivable in patients
with accessory renal arteries in whom only those arteries
amenable to catheter ablation are treated. In addition, due to
limitations in catheter manipulation in the typically smaller
accessory renal arteries, even if all arteries are treated, a less
pronounced BP reduction than reported in previous trials may
be expected. Importantly, the efﬁcacy of renal denervation inARAs
supply to the right kidney with similarly sized ren
artery. ARA ¼ accessory renal artery.patients with accessory renal arteries has not been studied.
Therefore, the purpose of the current study is to determine
whether renal denervation in patients with accessory renal
arteries (whether or not denervation in all renal arteries was
feasible) reduces BP to a similar degree as in patients with
bilateral single renal arteries.Methods
Study design and patients. This is a single-center, non-
randomized, uncontrolled retrospective analysis of hyper-
tensive patients with special anatomic considerations.
Patients age 18 years with a baseline systolic ofﬁce BP of
140 mm Hg despite 3 or more antihypertensive agents
were eligible for inclusion. Only patients with secondary
causes of hypertension were excluded.
Eligible patients were allocated to 2 groups: single renal
arteries only supplying both kidneys (group I) and accessory
renal arteries including those with more than 1 renal artery
supplying either kidney (group II). Importantly, patients
were considered to have accessory renal arteries if 1 or both
kidneys were supplied by dual main renal arteries of similar
size, 1 main and 1 or more additional renal arteries supplying
either the upper or lower pole, or a very early separation of
a pole artery from the main renal artery (Fig. 1). Group II
was further divided into 2 subgroups, group IIa including
patients with accessory renal arteries with denervation of all
arteries, and group IIb including patients with accessory
renal arteries with denervation of only the main renal artery
or some, but not all, accessory renal arteries.
The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki. All patients gave written
informed consent for the procedure, follow-up, and data
analysis.
Procedure. Renal denervation was performed with the
Symplicity catheter system (Medtronic, Mountain View,
California), including a radiofrequency catheter and a radio-
frequency generator. Before the treatment, patients received
a sedative, for example, midazolam, and an analgesic, foral arteries. (B) Shows a very early separation of a right pole artery. (C) Illustrates
Table 1. Characteristics of Renal Artery Anatomy in Patients
With ARA (Group II)
Characteristics of Renal
Artery Anatomy
Group IIa (ARA):
Completely Denervated
(n ¼ 9)
Group IIb (ARA):
Incompletely Denervated
(n ¼ 11)
Unilateral accessory
arteries
8 9
Left side 2 2
Right side 6 7
Separate renal artery 0 3
Early bifurcation with
pole artery
1 6
Dual main arteries 7 0
Bilateral accessory
arteries
1 2
Separate renal artery 0 0
Early bifurcation with
pole artery
1 2
Dual main arteries 1 2
Values are n.
ARA ¼ accessory renal artery.
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1087example, morphine, and appropriate systemic anticoagulation
with unfractionated intravenous heparin with a target acti-
vated clotting time >250 s. Femoral arterial access was
obtained with a 6-F sheath. First, nonselective angiography
of the abdominal aorta was performed to outline the
anatomy and to assess for the presence of accessory renal
arteries. Subsequently, selective angiography of all renal
arteries was performed with a 6-F guide catheter (typically
internal mammary or renal double curve). Common treat-
ment strategy in the main renal arteries includes the
application of radiofrequency energy in a circumferential
manner, aiming at a minimum of 4 ablation points at
8 W, as previously described (5,6). In the case of multiple
renal arteries, ablation was performed in all arteries with
a suitable diameter (>3.5 mm). To avoid vessel injury,
accessory arteries measuring 3.5 mm were not treated.
Final angiography was performed to rule out acute renal
artery injury.
Outcome analysis. Baseline data collection included a
detailed medical history, vital signs including heart rate,
3 ofﬁce BP measurements according to The Joint Na-
tional Committee guidelines for accurate ofﬁce BP
measurements (the average of which was used for data
analysis), 24-h ambulatory BP measurement and serum
creatinine. At 6-month follow-up, baseline examination
was repeated with an accepted time window of 2 weeks.
In addition, bilateral renal artery duplex imaging was
performed to rule out renal artery stenosis. If duplex
ultrasound detected questionable ﬁndings, especially in
accessory renal arteries, computed tomography angiog-
raphy or magnetic resonance angiography was performed.
Medication history and adverse events were reported at
baseline and at 6-month follow up.
The primary endpoint was the change in average ofﬁce
BP at 6-month follow-up compared with baseline. The BP
changes between the groups and subgroups were compared.
Secondary endpoints were the change in mean systolic 24-h
ambulatory BP and the number of antihypertensive medi-
cations at 6-month follow-up compared with baseline.
Safety endpoints included procedural complications and
renal artery stenosis at follow-up, as well as renal function
assessed by estimated glomerular ﬁltration rate (eGFR).
Statistical analysis. The values of all test parameters are
presented as the mean  SD. Within-group analyses were
performed with paired 2-tailed t tests comparing baseline
and 6-month values. Of note, there was no correction for
multiple comparisons. To compare BP reductions between
groups, an unpaired t test (group I vs. group II) and a 1-way
analysis of variance with the Dunnett post hoc test for
multiple comparisons (group I vs. IIa, and group I vs. group
IIb) were used. A 2-tailed p value of <0.05 was considered
statistically signiﬁcant. The statistical analyses were per-
formed with GraphPad InStat for Windows (version 3.10,
GraphPad Software, La Jolla, California).Results
All consecutive patients who underwent renal denervation
between February 2009 and January 2012 and completed the
6-month follow-up were screened for eligibility. Seventy-
four patients were enrolled, of whom 24 patients were
treated within a therapeutic renal denervation trial. Fifty-
four patients had single renal arteries only (group I), and in
20 patients (group II), accessory renal arteries were present.
Of the patients with accessory renal arteries, 17 patients had
unilateral and 3 patients bilateral accessory renal arteries
(Table 1). In 9 patients, all renal arteries, including accessory
arteries, were denervated (group IIa), whereas in 11 patients,
none or only some of the accessory renal arteries were
denervated (group IIb). Baseline characteristics are outlined
in Table 2.
Mean ofﬁce BP at baseline was 166.2/89.4  20.5/14.6
mm Hg in group I and 164.2/89.1  19.9/15.35 mm Hg
in group II (group IIa: 163.6/93.8  27/18.4 mm Hg;
IIb: 164.6/85.3  13.1/11.9 mm Hg). Baseline ambula-
tory BP was available in 54 patients in group I and in
18 patients in group II (IIa: 8; IIb: 10). Ambulatory
BP at baseline was 156.0/85.6  16.3/12.6 mm Hg
(group I) and 151.9/86.4  16.3/14.6 mm Hg (group II).
Heart rate at baseline was 66.9  12.6 beats/min in
group I and 67.6  11.5 beats/min in group II. Mean
number of antihypertensive medications at baseline was
4.2  1.4 (group I) and 4.4  1.4 (group II). Details
regarding antihypertensive medications are shown in
Table 3. Baseline eGFR was 81.6  22.4 ml/min/1.73 m2
(group I) and 84.7  23.2 ml/min/1.73 m2 (group II).
During the procedure, there were no serious adverse
events related to the device or procedure. Two patients
Table 2. Baseline Characteristics of All Treated Patients
Group I
(BSRA)
(n ¼ 54)
Group II
(ARA)
(n ¼ 20)
Group IIa
(Complete)
(n ¼ 9)
Group IIb
(Incomplete)
(n ¼ 11)
Mean age, yrs 64.5 59.1 54.1 63.8
Female, % 38.9 35 22.3 45.5
Mean ofﬁce BP, mm Hg 166.2/89.5 164.2/89.1 163.6/93.8 164.6/85.3
Mean 24-h BP, mm Hg 156.0/85.6 151.9/86.5 151.9/90.9 152/83
Mean heart rate, beats/min 66.9 67.6 66.8 68.4
Mean eGFR, ml/min/1.73 m2 81.6 84.7 92.4 78.3
Diabetes mellitus type 2, n 12 7 3 4
CAD, n 19 6 4 2
PAD, n 11 3 1 2
Hyperlipidemia, n 9 6 2 4
ARA ¼ accessory renal artery; BP ¼ blood pressure; BSRA ¼ bilateral single renal artery; CAD ¼ coronary artery disease;
eGFR ¼ estimated glomerular ﬁltration rate; PAD ¼ peripheral artery disease.
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1088experienced transient renal artery spasm during the proce-
dure (1 patient from group I, and 1 from group IIb). Mean
number of ablations in group I was 5.8  1.4 on the
right side and 5.7  1.7 on the left side, and 6.0  1.6 on
the right side and 6.2  2.9 on the left side in group II.
Mean number of ablations in patients of group IIa was
6.6  1.7 on the right side and 7.3  3.8 on the left side,
with an additional 6.3  3.5 ablations in the accessory renal
arteries. In group IIb, 5.4  1.3 and 5.2  1.5 ablations were
performed on the right and left side, respectively.
Mean ofﬁce BP at 6-month follow-up was 149.6/
82.7  21.4/14.5 mm Hg in group I and 158.0/88.9 
25.9/16.0 mm Hg in group II (group IIa: 154.8/94.9 
26.2/16.7 mm Hg; IIb: 160.5/84.0  26.6/14.2 mm Hg)
(Figs. 2A to 2C). In group I, there was an ofﬁce BP reduction
of 16.6  16.4 mm Hg systolic (p < 0.001) and 6.7 
11 mm Hg diastolic (p ¼ 0.016) 6 months after treatment,
whereas in group II, the ofﬁce systolic and diastolic BP re-
ductions were6.2 19.7mmHg and0.2 11.3mmHg,Table 3. Baseline Antihypertensive Medications in Group I and Group II
Antihypertensive Medications
Group I (BSRA)
(n ¼ 54)
Group II (ARA)
(n ¼ 20)
Patients on 5 antihypertensive drugs 46.3 60
Mean number of antihypertensive drugs 4.2  1.4 4.4  1.4
Diuretic 81.5 90
Beta-blocker 81.5 85
Calcium channel blocker 59.3 60
ACE inhibitor 35.2 35
Angiotensin receptor blocker 57.4 70
Renin inhibitor 35.2 25
Centrally acting sympatholytic agent 48.1 77.8
Vasodilator 7.4 5
Alpha1-blocker 16.7 5
Values are % or mean  SD.
ACE ¼ angiotensin-converting enzyme; other abbreviations as in Table 2.respectively (p ¼ 0.19 for systolic values, p ¼ 0.5 for
diastolic values). Group IIa had an ofﬁce BP reduction
of 8.8/1.1  17.9/10.8 mm Hg (p ¼ 0.2 for systolic
values), and group IIb of 4.1/1.3  20.8/11.6 mm Hg
(p ¼ 0.55 for systolic values) (Fig. 3).
There was a signiﬁcant difference in systolic and diastolic
ofﬁce BP reductions between patients with bilateral single
renal arteries (group I) and those with accessory renal arteries
(group II) (p ¼ 0.027 and p ¼ 0.016 for systolic and dia-
stolic BP, respectively). There was also a signiﬁcant differ-
ence in systolic ofﬁce BP changes between patients with
bilateral single renal arteries and those with accessory renal
arteries and incomplete or no denervation of the accessory
arteries (group IIb) (p ¼ 0.036); however, there was no
signiﬁcant difference in systolic BP changes between
patients with bilateral single renal arteries (group I) and
those with accessory renal arteries and complete denervation
of all arteries (group IIa) (p ¼ 0.14).
There was no signiﬁcant change in the mean number of
antihypertensive medications from baseline to 6-month
follow-up (group I: 4.2  1.5, p ¼ 0.9; group II: 4.4  1.5,
p ¼ 0.99). In 6 patients (group I: 3; group II: 3), the number
of medications was reduced, whereas in 3 patients (group I:
1; group II: 2), the number of antihypertensive medications
was increased before the 6-month follow-up.
Ambulatory 24-h BP 6 months after the procedure
was 147.7/80.5  16.4/11.3 mm Hg in group I. The
reduction in ambulatory BP compared with baseline
(systolic 8.3  17.4 mm Hg and diastolic 5.1  10.2
mm Hg) was statistically signiﬁcant (p ¼ 0.01 and
p ¼ 0.028 for systolic and diastolic, respectively). Group
II had a nonsigniﬁcant ambulatory BP change of sys-
tolic 3.7  8.3 mm Hg and diastolic 0.3  9 mm Hg
(p¼ 0.38 for systolic values). In both group IIa and IIb, there
were no signiﬁcant ambulatory BP reductions. Ambulatory
BP follow-up was available for only 6 and 8 patients,
Figure 2. Ofﬁce BP Changes in Groups I, II, and IIa and IIb
Boxplots of ofﬁce (BP) blood pressure values at baseline and 6-month follow-up (6M FU) are shown. The boxplots show maximum and minimum values, and medians
with upper and lower quartiles. (A) Ofﬁce blood pressure (BP) change in group I (bilateral single renal arteries [BSRA]). (B) Ofﬁce BP change in group II (accessory renal
arteries [ARA]). (C) Ofﬁce blood pressure change in group IIa and IIb.
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1089respectively. Three patients in each subgroup were lost to
ambulatory BP follow-up because of missed visits.
Heart rate at 6-month follow-up was 65.6  9.8 beats/
min in group I, and 64.2  8.1 beats/min in group II. Both
reductions (group I: 1.3  9.6 beats/min; group II: 3.4  8.9
beats/min) were considered as statistically not signiﬁcant
(p ¼ 0.55 and p ¼ 0.29, respectively).
In all groups, renal function, as assessed by serum creat-
inine and eGFR, was unchanged from baseline to 6-month
follow-up (group I: p ¼ 0.31, group IIa: p ¼ 0.14, group IIb:
p ¼ 0.5).
During 6-month follow-up, adverse events were observed
in 4 patients (7.4%): 2 patients underwent a coronary
intervention. One patient had an ST-segment elevation
myocardial infarction treated with percutaneous revascular-
ization. One patient was hospitalized for inpatient analgesictherapy of spinal disc herniation. The named adverse events
were classiﬁed as not related to the device or the procedure.
Discussion
Our ﬁndings demonstrate a BP reduction after catheter-
based renal denervation in patients with bilateral single renal
arteries. The magnitude of the 6-month ofﬁce BP reduction
(17/7 mmHg) was slightly less than that reported in previous
studies. Nevertheless, both ofﬁce and ambulatory BP reduc-
tions were statistically signiﬁcant. In the Symplicity HTN-1
trial including registry patients and the randomized Sym-
plicity HTN-2 trial, both of which excluded patients with
accessory renal arteries, 6-month BP reductions were 25/11
mm Hg and 32/12 mm Hg, respectively (5,6). It has been
shown that baseline systolic ofﬁce BP is a signiﬁcant predictor
Figure 3. Comparison of Ofﬁce BP Changes
Parallel boxplots of ofﬁce systolic pressure change (mm Hg) between baseline
and 6-month follow-up in groups I, II, IIa, and IIb. The boxplots present
maximum and minimum values, and medians with upper and lower quartiles
in each group. BP ¼ blood pressure.
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1090of efﬁcacy, with the highest BP reduction in patients with
a baseline systolic BP of >175 mm Hg (10,12). Therefore,
the more pronounced BP reduction might be related to the
higher baseline ofﬁce BP with 176/98 mm Hg in the
Simplicity HTN-1 trial as well as 178/97 mm Hg in the
Simplicity HTN-2 trial. This may also explain the slightly
lower reduction in ambulatory BP in patients with bilateral
single renal arteries in our study (8.3/5.1 mm Hg, p <
0.01) compared with Simplicity HTN-2 (11/7 mm Hg,
p ¼ 0.006). Of note, there was no signiﬁcant reduction in
ambulatory BP in patients with accessory renal arteries at 6-
month follow-up. Importantly, ofﬁce systolic and diastolic
BP reductions in patients with accessory renal arteries
(including those with complete or incomplete denervation)
were signiﬁcantly less than in patients with bilateral single
renal arteries. Moreover, systolic ofﬁce BP reductions in
patients with incompletely (including no) denervated acces-
sory renal arteries were signiﬁcantly less than in patients with
bilateral single renal arteries. Though reductions in systolic
ofﬁce BP in those with completely denervated accessory renal
arteries were also numerically less pronounced than in
patients with bilateral single renal arteries, this difference did
not reach statistical signiﬁcance. This may be related to a true
absence of a difference in BP reductions or to the small
number of patients in the latter subgroup with insufﬁcient
power to demonstrate a small difference.
The reason for the more modest BP reduction seen in
patients with accessory renal arteries is not clear. However,
renal sympathetic ﬁbers are found in all arteries supplyingthe kidneys, regardless of whether these are accessory renal
arteries or bilateral single renal arteries.
Therefore, the most plausible explanation is a more
incomplete interruption of the renal sympathetic ﬁbers in
patients with accessory renal arteries, either due to an
inability to denervate all accessory renal arteries or due to
a more conservative approach in smaller arteries because
circumferential catheter manipulation is not always safe.
Along these lines, absence of a BP reduction has been re-
ported in a patient with incomplete denervation (in whom
only 1 renal artery was denervated), emphasizing the
importance of complete denervation (11). To date, however,
data regarding the BP lowering effect in patients with
incompletely denervated renal arteries or accessory renal
arteries have not been reported.
There were no periprocedural complications. Speciﬁcally,
renal artery injury (e.g., dissection, occlusion, or renal artery
stenosis at follow-up) was not observed by renal artery duplex
imaging after 6 months. Furthermore, there were no adverse
events related to renal denervation at follow-up. The renal
function remained unchanged in all groups and subgroups.
Hence, denervation of accessory renal arteries of adequate
size is safe with the currently available Symplicity catheter.
Our ﬁndings have important implications. First, sympa-
thetic ﬁbers surrounding all arteries supplying the kidneys
appear to have an important role in BP regulation. Ablation
of accessory renal arteries of adequate size (>3.5 mm)
appears to be safe, and hence, a strategy aiming for complete
denervation should be pursued. Second, the BP reduction
even after complete denervation in patients with accessory
renal arteries appear to be lower than that seen in patients
with bilateral single renal arteries.
Study limitations. Our study is a nonrandomized single-
center study in which neither the investigators nor the patients
were blinded to the treatment. Selection and observer bias and
a placebo effect cannot be ruled out. The numbers of patients
in the subgroups were limited and do not allow deﬁnitive
statements regarding the importance of complete versus
incomplete denervation in patients with accessory renal arteries.
Likewise, the number of patients with 6-month ambulatoryBP
measurements in both subgroups of accessory renal arteries
(n ¼ 14) was too small to allow any conclusions regarding
the effect of renal denervation on 24-h ambulatory BP.
It is important to mention that our patients did not
undergo routine invasive imaging at follow-up, and all
noninvasive imaging strategies have limited utility in the
visualization of and detection of stenosis in accessory renal
arteries. Hence, it is conceivable that accessory renal artery
stenosis was missed at follow-up.
Conclusions
BP reduction after renal denervation appears to be less
pronounced in patients with accessory renal arteries than in
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1091patients with bilateral single renal arteries, particularly if they
are incompletely denervated. The number of patients in our
study was limited; therefore, further studies are needed
before deﬁnitive conclusions can be made. If our ﬁndings are
conﬁrmed, this could have important implications for
patient selection and device technology. Future device
generations should allow safe and complete denervation of
all, including accessory renal arteries.
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